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Aims A signiﬁcant increase in congestive heart failure (CHF) was reported when the anti-ErbB2 antibody trastuzumab was
used in combination with the chemotherapy drug doxorubicin (Dox). The aim of the present study was to investigate
the role(s) of miRNAs in acute Dox-induced cardiotoxicity.
Methods
and results
Neuregulin-1-ErbB signalling is essential for maintaining adult cardiac function. We found a signiﬁcant reduction in
ErbB4 expression in the hearts of mice after Dox treatment. Because the proteasome pathway was only partially
involved in the reduction of ErbB4 expression, we examined the involvement of microRNAs (miRs) in the reduction
of ErbB4 expression. miR-146a was shown to be up-regulated by Dox in neonatal rat cardiac myocytes. Using a luci-
ferase reporter assay and overexpression of miR-146a, we conﬁrmed that miR-146a targets the ErbB4 3′UTR. After
Dox treatment, overexpression of miR-146a, as well as that of siRNA against ErbB4, induced cell death in cardiomyo-
cytes. Re-expression of ErbB4 in miR-146a-overexpressing cardiomyocytes ameliorated Dox-induced cell death. To
examine the loss of miR-146a function, we constructed ‘decoy’ genes that had tandem complementary sequences for
miR-146a in the 3′UTR of a luciferase gene. When miR-146a ‘decoy’ genes were introduced into cardiomyocytes,
ErbB4 expression was up-regulated and Dox-induced cell death was reduced.
Conclusion These ﬁndings suggested that the up-regulation of miR-146a after Dox treatment is involved in acute Dox-induced
cardiotoxicity by targeting ErbB4. Inhibition of both ErbB2 and ErbB4 signalling may be one of the reasons why those
patients who receive concurrent therapy with Dox and trastuzumab suffer from CHF.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords MicroRNA † Neuregulin † Cardiomyocyte
1. Introduction
Neuregulin-1 (NRG-1) is an agonist for receptor tyrosine kinases of
the epidermal growth factor receptor (EGFR) family, consisting of
EGFR/HER1/ErbB1, ErbB2/HER2, ErbB3/HER3, and ErbB4/HER4.
1
With the exception of ErbB2, which has no ligand, the ErbB proteins
have a ligand-binding ectodomain, a single transmembrane segment,
an intracellular tyrosine kinase domain, and a tyrosine-rich carboxy
terminus.
2 Among them, ErbB2 and ErbB4 are expressed in differen-
tiated cardiomyocytes.
3 Binding of NRG-1 to ErbB4 increases its
kinase activity and leads to heterodimerization with ErbB2 or homo-
dimerization with ErbB4 and stimulation of intracellular signal trans-
duction pathways.
4 Heterodimers with ErbB2 appear to be a more
potent signalling complex than homodimers.
5
Clinical observations clearly suggested increased cardiotoxicity of
anthracyclines in patients receiving trastuzumab, a monoclonal
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6 Therefore, we ﬁrst examined changes in
ErbB2 and ErbB4 expression levels after stimulation with doxorubicin
(Dox). Interestingly, Dox signiﬁcantly reduced the protein expression
of ErbB4 in the heart, although it did not affect ErbB2 expression.
Several reports indicated that WW domain containing E3 ubiquitin
protein ligase 1 targets the full-length ErbB4 for ubiquitin-mediated
degradation in breast cancer;
7 therefore, we pre-treated neonatal rat
cardiac myocytes (NRCMs) with MG132, a proteasome inhibitor.
However, MG132 could not fully abolish the reduction in ErbB4
expression after stimulation with Dox. This suggested that there may
be other mechanisms for the reduction in ErbB4 protein expression.
MicroRNAs (miRNAs or miRs) are small, non-coding RNAs that
modulate mRNA stability and post-transcriptional translation.
8
miRNAs are of crucial importance for the heart to develop and func-
tion properly. It has already been shown that loss of cardiac miRNA-
mediated regulation by Dgcr8 or Dicer gene deletion lead to dilated
cardiomyopathy and heart failure.
9,10 Furthermore, speciﬁc deletion
of cardiac miR-1 or miR-133 lead to embryonic lethality and heart
failure.
11,12 Recently, DNA-damage-induced up-regulation of pre-
miRNAs and mature miRNAs was demonstrated in vitro.
13 Therefore,
we speculated that anthracycline-induced injury is partly mediated by
the induction of miRNAs that targets ErbB4.
It is well known that reactive oxygen species (ROS) are involved
in Dox-induced cardiotoxicity.
14,15 Previous reports suggested that
miR-146a is up-regulated by nuclear factor (NF)-kB, which is a
downstream mediator of ROS.
16–18 Because miR-146a is abundantly
expressed in the heart and ErbB4 has three potential miR-146a-
binding sites in the 3′UTR, we examined the function of miR-146a
in the heart after Dox treatment. In the present study, we found
that (i) Dox reduced ErbB4 expression in the heart; (ii) miR-146a
was up-regulated by Dox and overexpression of miR-146a reduced
ErbB4 expression; (iii) miR-146a enhanced Dox-induced cell death
as well as siRNA against ErbB4; (iv) re-expression of ErbB4 in
miR-146a-overexpressing cardiomyocytes suppressed the increase in
Dox-induced cell death; and (v) the loss of miR-146a function with
‘decoy’ genes up-regulated ErbB4 expression and reduced
Dox-induced cell death.
These ﬁndings suggest that the up-regulated expression of
miR-146a after Dox treatment is involved in acute Dox-induced car-
diotoxicity by targeting ErbB4.
2. Methods
2.1 Reagents
Antibodies and reagents used in this study are summarized in the Sup-
plementary methods.
2.2 Isolation of NRCMs
The investigation conformed to the Guide for the Care and Use of Lab-
oratory Animals published by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996) and was approved by Kyoto Univer-
sity Ethics Review Board (Med Kyo 09280). NRCMs were prepared as
described previously.
19
2.3 Mice
Male C57BL/6 mice were purchased from Japan SLC Inc. (Shizuoka, Japan)
and maintained in a speciﬁc pathogen-free facility.
2.4 Plasmids
Expression vectors for the negative control (miR-control) and the
miRNAs were generated using BLOCK-iTTM PolIImiR RNAi Expression
Vector Kits (Invitrogen). The sequences of all constructs were analysed
using an ABI 3100 genetic analyzer. All of the constructs were inserted
correctly into a pLenti6/V5-D-TOPO vector (Invitrogen) driven by a
CMV promoter to stably express genes in NRCMs.
20
2.5 siRNA-mediated knockdown of rat ErbB4
The oligonucleotides used for siRNA of ErbB4 are indicated in the Sup-
plementary methods.
Randomly shufﬂed forms of the ErbB4 siRNA1 were used as a control
(control-siRNA). Every siRNA construct was made using a pSINsi-mU6
vector (Takara Bio Inc.) and the siRNA constructs were introduced to
a lentivirus vector plasmid and used for transfection of NRCMs.
20
2.6 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay
Cellswerelabelledwith3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide(MTT)ataﬁnalconcentrationof0.5 mg/mLforatleast4 hat378C.
21
Viabilitywasthenevaluatedbymeasuringthe absorbance at595 nmusing an
El × 800 MicroplateReader (BIO-TEK Instruments, Inc.). The absorbance of
thecontrolcellswithouttreatmentwasconsideredas100%viability,andthe
resultswereexpressedasthepercentviabilityincomparisonwiththecontrol
cells.
2.7 Western blotting
Cell lysates were prepared as described previously and subjected to
sodium dodecyl sulfate–polyacrylamide gel electrophoresis followed by
standard western blotting procedures.
19
2.8 Quantitative real-time-polymerase chain
reaction for mRNA and miRNA
Total RNA was isolated using TRIzol
w reagent (Invitrogen). cDNA was
synthesized using SuperScript II reverse transcriptase (Invitrogen) and
polymerase chain reaction (PCR) was performed with a SYBR Green
PCR master mix (Applied Biosystems), normalized with GAPDH. Gene-
speciﬁc primers are indicated in the Supplementary methods. miRNAs
were quantiﬁed in accordance with TaqMan MicroRNA Assays (Applied
Biosystems), normalized with U6 snRNA. An ABI Prism 7900HT sequence
detection system was used as a thermal cycler.
2.9 Dual-luciferase assays (3′UTR assay)
PCR fragments were ampliﬁed from human or rat cDNAs and subcloned
downstream of a CMV-driven Fireﬂy luciferase cassette in a pMIR-
REPORT vector (Ambion). To make wild-type or mutant ErbB4 3′UTR
luciferase reporters, about 100 bp oligonucleotides around binding site
3 were annealed and inserted into a pMIR-REPORT vector. An internal
control reporter, Renilla reniformis luciferase, driven by the thymidine
kinase (TK) promoter (pRL-TK: Promega) was also co-transfected to nor-
malize the transfection efﬁciency.
2.10 Measurement of mitochondrial
membrane potential by ﬂow cytometry
TMRE dye (100 nM) was added and staining was performed at 378C for
30 min. Then, the cells were washed once with phosphate-buffered
saline (PBS), re-suspended in PBS at 48C, and kept on ice. Flow cytometry
was performed immediately using a FACS Aria (Beckman Dickinson).
Appropriate compensation was set. For each sample, data from
.30 000 cells were collected. The ratio of TMRE intensity of cardiomyo-
cytes with Dox compared with cardiomyocytes without Dox for each
group was calculated as a percentage and plotted on the graph.
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cytometry
AnnexinV and propidium iodide (PI) staining was performed using a
Vybrant
w Apoptosis Assay kit #2 (Molecular Probes) in accordance
with the manufacturer’s protocol. The proportions of apoptotic cells
(AnnexinV-positive and PI-negative: Q2), and the total number of dead
cells (AnnexinV-positive: Q2 + Q4) and live cells (AnnexinV-negative
and PI-negative: Q3) were analysed by ﬂow cytometry using a FACS
Aria. Appropriate compensation was set. For each sample, data from
.30 000 cells were collected.
2.12 Statistics
Data are presented as means+SE. Statistical comparisons were per-
formed using unpaired two-tailed Student’s t-tests or one-way analysis
of variance with Bonferonni’s post hoc test where appropriate, with a
probability value of ,0.05 taken to indicate signiﬁcance.
3. Results
3.1 ErbB4 expression was decreased by
Dox treatment in vivo and in vitro
We examined the expression of ErbB2 and ErbB4 in the hearts of
mice that had received a single intraperitoneal injection of Dox
(20 mg/g).
22 We found that ErbB4 expression was signiﬁcantly
reduced 1 day after Dox injection and recovered to the control
level 5 days after injection. On the other hand, ErbB2 expression
was not affected (Figure 1A and B). The reduction of ErbB4 expression
was also observed in NRCMs in a time-dependent manner, whereas
ErbB2 expression was not altered (Figure 1C). Figure 1D shows that
Dox did not increase the level of cleaved-ErbB4 (80 kDa) in
NRCMs. This was the same in the hearts of mice after Dox injection
(see Supplementary material online, Figure S1). These data indicated
that the acute reduction in ErbB4 level after Dox was not the
result of protein shedding. We also examined the possible involve-
ment of the ubiquitin–proteasome pathway in the reduction of
ErbB4 level after Dox treatment. As shown in Figure 1E, MG132,
a proteasome inhibitor, ameliorated the Dox-induced reduction in
ErbB4 levels. However, the effect was limited and ErbB4 expression
did not recover to the basal level. These ﬁndings suggested that
there might be other pathways that regulate ErbB4 expression.
3.2 miR-146a was up-regulated in
Dox-treated NRCMs
It is well known that ROS are involved in Dox-induced cardiotoxi-
city.
14,15 Previous reports suggested that miR-146a is up-regulated by
NF-kB, which is a downstream mediator of ROS.
16–18 Because
miR-146a is abundantly expressed in the heart
23 and ErbB4 has three
potential miR-146a-binding sites in the 3′UTR (TargetScan4.0: http://
www.targetscan.org/; see Supplementary material online, Figure S2A),
weexaminedthefunctionofmiR-146aintheheartafterDoxtreatment.
We compared the expression of miR-146a between NRCMs and
cardiac ﬁbroblasts and conﬁrmed that miR-146a was predominantly
expressed in NRCMs as well as miR-133a (see Supplementary material
online,FigureS2BandC).AsshowninFigure2AandB,miR-146awassig-
niﬁcantlyup-regulatedinadose-dependentmanner,anditslevelpeaked
at16 hafterDoxtreatment. Next, we overexpressedmiR-146a usinga
lentivirus vector in NRCMs.
20 The transduction efﬁciency was always
over 90%, as shown in the Supplementary material online, Figure S2D.
The protein level of ErbB4 was signiﬁcantly reduced in miR-146a-over-
expressing NRCMs, whereas ErbB2 levels were not altered (Figure 2C
Figure 1 ErbB4 expression was decreased after Dox treatment in vivo and in vitro.( A) Immunoblotting for ErbB4 and ErbB2 in the hearts of mice
after intraperitoneal injection of Dox (20 mg/g). (B) Densitometry for ErbB4 after intraperitoneal injection of Dox. Values are the means+SE of three
independent experiments (
##P , 0.01 vs. 0 h). (C) Immunoblotting for ErbB4 and ErbB2 in NRCMs after Dox treatment. (D) Immunoblotting for
ErbB4 in NRCMs after Dox treatment. Because the antibody against ErbB4 recognizes the C-terminus of ErbB4, full length of ErbB4 is present at
180 kDa and cleaved-ErbB4 is present at 80 kDa. Note that cleaved-ErbB4 was not seen at 80 kDa. (E) NRCMs were pre-treated with or
without proteasome inhibitor MG132 for 1 h and then treated with Dox for 24 h.
T. Horie et al. 658and D). mRNA levels of ErbB4 are shown in Figure 2E. In 293T cells, a
human embryonic kidney cell line, miR-146a overexpression also
reduced ErbB4 expression (see Supplementary material online, Figure
S2E). To verify which binding site was most important, we performed
a luciferase reporter assay in 293T cells. We ampliﬁed a  500 bp frag-
ment of the ErbB4 3′UTR from either human or rat cDNAs and cloned
these into downstream of a CMV-driven luciferase reporter gene. We
found that the most conserved binding site (site 3) was important in
both human and rat (see Supplementary material online, Figure S2F
and G). Figure 2F shows that miR-146a overexpression reduced the
ErbB4 3′UTR luciferase activity (site 3), whereas miR-133a, one of the
most abundant miRNAs in the heart, did not affect luciferase activity.
Introduction of mutations in the miR-146a-binding site abolished the
miR-146a-mediated inhibition of ErbB4 3′UTR luciferase activity
(Figure 2G; see Supplementary material online, Figure S2H). Dox
reduced wild-type ErbB4 3′UTR luciferase activity in NRCMs. Conver-
sely, this reduction was not observed in an ErbB4 3′UTR reporter that
had mutations in the miR-146a-binding site (Figure 2H). These results
Figure 2 ErbB4 is a target for miR-146a. (A) qRT-PCR for miR-146a after Dox for 16 h at the indicated concentrations in NRCMs. Values are the
means+SE of three to four independent experiments (
#P , 0.05,
##P , 0.01). (B) qRT-PCR for miR-146a after Dox (1 mM) for the indicated times
in NRCMs. Values are the means+SE of three to four independent experiments (
#P , 0.05). (C) Immunoblotting for ErbB4 and ErbB2 in miR-
control or miR-146a-overexpressing NRCMs. (D) Densitometry for ErbB4 in miR-control or miR-146a-overexpressing NRCMs (
#P , 0.05).
(E) qRT-PCR analysis for ErbB4 in miR-control or miR-146a-overexpressing NRCMs. Values are the means+SE of four independent experiments
(n.s.; not signiﬁcant). (F) ErbB4 3′UTR Fireﬂy luciferase (F-luc) activity at binding site 3 in 293T cells. Values are the means+SE of four independent
experiments (
#P , 0.05). (G) ErbB4 3′UTR F-luc activity at binding site 3 in 293T cells. Values are the means+SE of four independent experiments
(
#P , 0.05). (H) ErbB4 3′UTR F-luc activity at binding site 3 in NRCMs. Values are the means+SE of six independent experiments (
#P , 0.05).
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treatment can affect myocardial ErbB4 expression
post-transcriptionally.
3.3 Both miR-146a overexpression and
ErbB4 knockdown reduced NRCM survival
after Dox treatment
To evaluate the effect of miR-146a induction after Dox treatment on
cardiac myocytes, we stimulated miR-146a-overexpressing NRCMs
using Dox. Dox induced more cell death in miR-146a-overexpressing
NRCMs than miR-control (negative control) NRCMs, which was
shown in microscopy images (see Supplementary material online,
Figure S3A) and in cell viability assays using MTT (Figure 3A). These
data suggested that the up-regulation of miR-146a may be harmful in
cardiac myocytes. Dox reduced ErbB4 expression and increased
cleaved caspase 3 expression, which is a sensitive apoptosis marker
(Figure 3B), and miR-146a levels increased at the same time (Figure 2A
and B). Therefore, we speculated that Dox-induced apoptosis resulted
from thedown-regulationofErbB4 bymiR-146a. Toverify thefunction
Figure 3 Both miR-146a overexpression and ErbB4 knockdown reduced NRCMs survival after Dox treatment. (A) MTT assay of NRCMs trans-
duced with miR-control or miR-146a with or without Dox treatment for 24 h. Values are the means+SE of six independent experiments (
#P , 0.05,
##P , 0.01). (B) Immunoblotting for ErbB4, bcl-2, and cleaved caspase 3 after Dox in NRCMs. (C) Immunoblotting for ErbB4 in NRCMs transduced
with control-siRNA (scrambled) or ErbB4-siRNAs. (D) Densitometry for ErbB4 in NRCMs transduced with ErbB4-siRNA. Values are the means+SE
of three independent experiments (
#P , 0.05,
##P , 0.01). (E) MTT assay of NRCMs transduced with control-siRNA or ErbB4-siRNA with or
without Dox treatment for 24 h. Values are the means+SE of six independent experiments (
##P , 0.01). (F) Immunoblotting for ErbB4, pAkt,
tAkt, and cleaved caspase 3 in NRCMs, infected with control-siRNA or ErbB4-siRNAs with or without Dox treatment for 24 h. (G) Flow cytometric
analysis of TMRE in NRCMs transduced with control-siRNA or ErbB4-siRNA with or without Dox treatment for 24 h. The X-axis represents TMRE
intensity (PE intensity) and the Y-axis represents cell number. Red populations indicate the TMRE high group and blue populations indicate the TMRE
low group. (H) The ratio of TMRE intensity with Dox compared with without Dox for each group. Values are the means+SE of three to four inde-
pendent experiments (
#P , 0.05).
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introduced into NRCMs. The knockdown efﬁciency of these siRNAs
was 50 and 10%, respectively, at the protein level (Figure 3C and D).
Knockdown of ErbB4 exaggerated Dox-induced cell death in the
MTT assay, according to the knockdown efﬁciency (Figure 3E). Knock-
down of ErbB4 reduced Dox-induced Akt activation and increased the
amount of cleaved caspase 3 (Figure 3F). We also evaluated mitochon-
drial function using TMRE dye. TMRE is a cell-permeant, cationic,
red-orange ﬂuorescent dye that is readily sequestered by active mito-
chondria.
24 Fluorescence microscopy images of NRCMs with or
without Dox are shown in the Supplementary material online, Figure
S3B.WemeasuredtheintensityofTMREstaining,whichindicatesmito-
chondrial membrane potential, using ﬂow cytometry. In the basal state,
about 80% of cells resided in the TMRE high population (red) and 20%
cells in the TMRE low population (blue). After Dox treatment, the
TMRE high population and TMRE intensity were reduced in ErbB4
knocked-down NRCMs, according to the knock-down efﬁciency
(Figure 3G and H).
3.4 miR-146a enhanced Dox-induced
apoptosis in NRCMs
Both overexpression of miR-146a and ErbB4 siRNA2 reduced levels
of ErbB4 expression, Akt phosphorylation, and bcl-2 expression and
increased cleaved caspase 3 level after Dox treatment in NRCMs
(Figure 4A). The TMRE high population and TMRE intensity after
Dox were more reduced in miR-146a-overexpressing NRCMs than
in control cells (Figure 4B and C). These results indicated that
miR-146a enhanced Dox-induced apoptosis in NRCMs. Following the
transduction of ErbB4 without a 3′UTR in miR-146a-overexpressing
NRCMs, the increase in Dox-induced cleaved caspase 3 was
reduced to the control level (Figure 4D and E). The intensity of
TMRE staining also recovered to the control level (see Supplementary
material online, Figure S4A and B).
3.5 Reduction of endogenous miR-146a
ameliorated Dox-induced apoptosis in
NRCMs
To assess the functional consequences of silencing endogenous
miR-146a in vitro, NRCMs were infected with a lentivirus vector, in
which three or six tandem sequences partially complementary to
miR-146a were linked to a luciferase or GFP reporter gene in their
3′UTRs (see Supplementary material online, Figure S5A and F). The
complementary sequences acted as a decoy, sequestering endogen-
ous miR-146a and other miRNAs with the same seed sequences
(see Supplementary material online, Figure S5H).
20,25–27 Transfection
with a luciferase-decoy gene along with miR-146a reduced the
Figure 4 miR-146a enhanced Dox-induced apoptosis in NRCMs. (A) Immunoblotting for ErbB4, pAkt, tAkt, bcl-2, and cleaved caspase 3 in NRCMs
transduced with miR-control, miR-146a, or ErbB4-siRNA2 in the presence or absence of Dox for the indicated time periods. (B) Flow cytometric
analysis of TMRE in NRCMs transduced with miR-control of miR-146a with or without Dox for 24 h. (C) The ratio of TMRE intensity with Dox
compared with without Dox for each group. Values are the means+SE of three to four independent experiments (
##P , 0.01). (D) Immunoblotting
for cleaved caspase 3 in miR-control or miR-146a-overexpressing NRCMs infected with either lacZ or ErbB4 with or without Dox for 24 h. (E) Den-
sitometry for cleaved caspase 3 in miR-control or miR-146a-overexpressing NRCMs infected with either lacZ or ErbB4 with or without Dox for 24 h.
Values are the means+SE of four independent experiments (
#P , 0.05,
##P , 0.01).
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anti-miR-146a × 6 than that with anti-miR-146a × 3 in 293T cells,
whereas transfection along with miR-control or miR-133a did not
reduce luciferase activity (see Supplementary material online, Figure
S5B–D). When the same amount of plasmids of control and decoy
gene were transduced into NRCMs, luciferase activity was signiﬁcantly
reduced (see Supplementary material online, Figure S5E). NRCMs
infected with GFP-decoy (see Supplementary material online, Figure
S4F) reduced the intensity of GFP in ﬂow cytometry (see Supplemen-
tary material online, Figure S5G). These results indicated that endogen-
ous miR-146a speciﬁcally bound to the decoy gene and inhibited the
translation of luciferase or GFP in NRCMs. The expression of
miR-146a was signiﬁcantly reduced in NRCMs infected with
decoy-miR-146a × 6( Figure 5A). ErbB4 expression was increased sig-
niﬁcantly in NRCMs infected with decoy-miR-146a × 6( Figure 5B and
C). Decoy-miR-146a ameliorated the Dox-induced reduction of
ErbB4 and Dox-induced increase in cleaved caspase 3 (Figure 5D–
F). TMRE intensity was signiﬁcantly increased in NRCMs infected
with decoy-miR-146a × 6 compared with control cells (see Sup-
plementary material online, Figure S5I and J).
3.6 AnnexinV and PI staining of NRCMs
Finally, we stained NRCMs with AnnexinV/PI and then measured the
numbers of apoptotic cells, dead cells, and live cells using ﬂow cyto-
metry. Figure 6A shows that the numbers of apoptotic and dead cells
were increased after Dox treatment. Transfection of miR-146a or
Figure 5 Reduction in endogenous miR-146a ameliorated Dox-induced apoptosis in NRCMs. (A) qRT-PCR analysis for miR-146a in NRCMs,
infected with control-decoy (no binding site) or decoy-miR-146a (anti-miR-146a × 6) using lentivirus vector. Values are the means+SE of three
independent experiments (
##P , 0.05). (B) Immunoblotting for ErbB4 in NRCMs infected with control-decoy or decoy-miR-146a. (C) Densitometry
for ErbB4 in NRCMs infected with control-decoy or decoy-miR-146a. Values are the means+SE of four independent experiments (
#P , 0.05). (D)
Immunoblotting for ErbB4, bcl-2, and cleaved caspase 3 in NRCMs infected with control or decoy gene in the presence or absence of Dox for the
indicated time periods. (E) Densitometry for ErbB4 in NRCMs infected with control or decoy gene in the presence or absence of Dox. Values are the
means+SE of four independent experiments (
#P , 0.05). (F) Densitometry for cleaved caspase 3 in NRCMs infected with control or decoy gene in
the presence or absence of Dox. Values are the means+SE of four independent experiments (
#P , 0.05).
T. Horie et al. 662ErbB4 siRNA induced apoptosis and cell death, whereas transfection
of decoy-miR-146a (anti-miR-146a × 6) reduced these in NRCMs
after treatment with Dox (Figure 6B–D).
4. Discussion
Intensive investigations into Dox-induced cardiotoxicity have been
ongoing for decades. In the present study, we have clariﬁed for the
ﬁrst time that miR-146a-mediated suppression of ErbB4 is a substan-
tial causal mechanism of Dox-induced cardiac toxicity.
NRG-1/ErbB signalling is best known for its indispensable role
during cardiac and neuronal development. The importance of the
physiological role of ErbB signalling in the post-natal heart was
demonstrated by analysing the hearts of conditional mutant mice.
ErbB2-deﬁcient conditional mutant mice were viable; however, phys-
iological analysis revealed the onset of multiple independent par-
ameters of dilated cardiomyopathy.
28,29 Conditional inactivation of
ErbB4 in ventricular muscle cells also led to a severe dilated cardio-
myopathy.
30 Heterozygous knockout of NRG-1 in mice worsens sur-
vival and left ventricular function in the presence of Dox-induced
cardiac injury.
31 These reports showed the importance of NRG-1/
ErbB signalling not only during development but also after birth.
Observations in patients treated with trastuzumab (Herceptin), an
inhibitory antibody against ErbB2, which is administered with or fol-
lowing anthracyclines in breast cancer, suggested that ErbB-mediated
myocardial protection against cardiotoxic drugs is also prominent in
the human heart.
6 Despite extensive research, a signiﬁcant increase
in cardiotoxic effects of concurrent treatment with an anthracycline
and trastuzumab has remained difﬁcult to explain. Trastuzumab cardi-
otoxicity appears to be dose independent and largely reversible,
suggesting a different mechanism from that of anthracyclines.
32
From the present results, it is possible that the transient reduction
in ErbB4 expression via miR-146a up-regulation and/or ubiquitin–
proteasome activation by Dox worsens the cardiotoxic effects of
trastuzumab, an inhibitor of ErbB2, by complete shutdown of the
NRG-1/ErbB pathway. Because the reduction of ErbB4 by Dox was
reversible in the present experiments, changing the timing of Dox
and trastuzumab administration may reduce their cardiotoxic
effects. Other strategies for the prevention of side effects may
include limits on the amount of Dox and administration of Dox in
combination with NRG-1.
It is well known that ROS are involved in Dox-induced cardiotoxi-
city, and the generation of ROS can be interpreted by the chemical
structure of Dox, which possesses a tendency to generate ROS
during drug metabolism.
14,15 Recent ﬁndings indicate that the endo-
thelial nitric oxide synthase reductase domain converts Dox to an
unstable semiquinone intermediate that favours ROS generation.
15
Because ROS serve as an upstream mediator for the activation of
NF-kB,
33,34 and a number of previous reports have suggested that
miR-146a transcription is regulated by NF-kB,
16–18 miR-146a induc-
tion by Dox in our experiment may be due to ROS-mediated
NF-kB activation. Several reports suggested that there are inhibitory
kB kinase-dependent or independent pathways for the activation of
NF-kB by Dox in vitro.
35,36 Further examinations are required in
order to determine the precise mechanisms for the induction of
miR-146a by Dox in vivo.
NRG-1 is reported to be predominantly expressed in the cardiac
microvascular endothelium and to have beneﬁcial effects on cardio-
myocytes through the Akt and Erk pathway.
37 NRG-1b has been
reported to be 10–100 times more active than NRG-1a.
38,39 We
performed immunoblotting and quantitative real-time (qRT)-PCR
for NRG-1b and detected NRG-1b in NRCMs. Therefore, NRG-1
is one of the factors that protect cardiomyocytes in an autocrine or
paracrine manner, although it is possible that NRCMs may express
much more NRG-1b than adult cardiac myocytes. Dox reduced the
expression of NRG-1b (see Supplementary material online, Figure
S6A). miR-146a and knockdown of ErbB4 increased NRG-1b
expression at the mRNA and protein levels (see Supplementary
Figure 6 AnnexinV and PI staining of NRCMs. (A) Dot-plot analysis of AnnexinV/PI staining showed that apoptotic cells (Q4) and dead cells
(Q2 + Q4) were increased after Dox treatment for 24 h. (B) The percentages of apoptotic cells after Dox treatment. (C) The percentages of
dead cells after Dox treatment. (D) The percentages of live cells after Dox treatment. Values are the means+SE of six independent experiments
(
#P , 0.05,
##P , 0.01).
Involvement of miR-146a in doxorubicin cardiotoxicity 663material online, Figure S6B–E). We do not know the reason why
NRG-1b was up-regulated following miR-146a overexpression or
knockdown of ErbB4, but there may be a negative feedback loop
between ErbB4-NRG-1b to compensate for the reduction in ErbB4
expression.
In conclusion, the present results suggest that the up-regulated
expression of miR-146a after Dox treatment is involved in acute Dox-
induced cardiotoxicity by targeting ErbB4. There is emerging evidence
for the involvement of NRG-1/ErbB signals in heart failure. Therefore,
the development of new therapeutic strategies based on NRG-1, such
as the delivery of nucleotides that inhibit miR-146a, is promising for
treating heart failure.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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